What the trial was testing
The trial enrolled 230 patients with colorectal cancer. The study was sponsored by National Cancer Institute, Naples and tracked outcomes across the full group of patients who matched the trial's eligibility profile.
It was a large trial designed to confirm whether the treatment works well enough for wider use. Trials at this stage are designed to produce evidence regulators and physicians can act on — not just observations to follow up later.
What the results showed
People who received bevacizumab 4 days before chemotherapy lived a median of 29.8 months compared to 24.1 months with same-day dosing.
JAMA network open · 2021 · NCT01718873
These findings — that people lived nearly 6 months longer when bevacizumab was given before chemotherapy instead of same-day — were published in the JAMA network open and represent the headline result of the study.
Researchers tracked outcomes across 230 patients enrolled in the trial. The result was consistent enough across the group that the team felt confident reporting it.
What this means for patients
For patients with colorectal cancer, this result changes the calculus on what to ask their care team about. Whether it changes day-to-day care depends on factors like disease subtype, prior treatments, and where the patient is in their care journey.
What you can do now
Bevacizumab is already FDA-approved for metastatic colorectal cancer. This study suggests timing matters—giving it a few days before chemotherapy may help people live longer with fewer side effects. Talk to your oncologist about whether this scheduling approach might work for you.
Eligibility for the treatments mentioned above depends on specific test results and clinical history. Bring this summary, the trial name, and your most recent labs or pathology report to your next visit.
Open colorectal cancer trials
A Study for Imaging the Lower Gastrointestinal Tract Using a Retro-TCE Capsule
The investigators have developed an inexpensive tool to take pictures in the lower GI tract without sedation and to look for signs of disease. The tool is a capsule, about the size of a fish oil or multi-vitamin supplement, attached to a string. The capsule and string are connected to a motor to allow the capsule to advance up the participant's lower GI tract. The capsule will be inserted into the participant's lower GI tract and advance upward via a slow spiral motion. The capsule is connected to an imaging system that saves and displays the images in real time.
Feasibility of Online MR-guided Radiotherapy on a 1.5T MR-Linac
This study investigates the feasibility of imaging and treatment on a novel 1.5 T MR-Linac radiotherapy hybrid device.